WO2012030142A2 - Composition for treating prostate cancer including spikenard extract - Google Patents

Abstract

The present invention relates to a novel usage of spikenard extract, and more particularly, to a composition for preventing and treating prostate cancer containing spikenard organic solvent extract. The composition for treating prostate cancer, according to the present invention, effectively suppresses the growth of prostate cancer cells and induces apoptosis, and thus can be effectively used for treating and preventing prostate cancer.

Description

Composition for the treatment of prostate cancer comprising extract

The present invention relates to a novel use of persimmon extract. In particular, the present invention relates to a therapeutic composition containing as an active ingredient extracts persimmon extract showing excellent prophylactic or therapeutic efficacy against prostate cancer.

The prostate is an organ that exists only in males that makes up part of the semen and is located below the bladder and adjacent to the rectum. Prostate cancer is a malignant tumor that occurs in the prostate gland, and is one of the most common cancers among men in the West, and it is the fastest growing cancer in men due to recent dietary habits in Korea. do. In developed countries such as North America and Western Europe, it is the most common cancer that accounts for about 20% of male cancers, and the United States has the highest frequency of male cancers occurring annually, and ranks second after lung cancer among cancer deaths. In Korea, the incidence of prostate cancer has increased significantly in recent years due to an increase in life expectancy, an increase in the elderly, westernization of a diet, development of diagnostic technology, and increased awareness of prostate cancer. According to the central cancer registration data, the cancer incidence fraction of prostate cancer was 6th in 2001, 2.7% of male cancers and 3.0% in 2002, and it is the fastest growing in recent years and is expected to increase further. to be. Prostate cancer is known to be caused by hormones, dietary habits, and chemicals in addition to genetic predisposition.

Most prostate cancers are cancers of gland cells in the prostate, which spread well to lymph nodes and bones. About 90% of prostate cancers are proliferated by male hormones that are produced in your body. For this reason, hormonal therapies that inhibit cancer growth and kill some of the cancer cells by inhibiting the action of male hormones are most commonly used in the treatment of prostate cancer (Greenlee, R. T et al., Cancer statistics.CA Cancer J. Clin 50: 7 (2000).

Treatments for prostate cancer include (a) radical prostatectomy (b) radiation (c) chemotherapy (d) hormonal therapy. The most widely used treatment is hormonal therapy, which is a so-called androgen removal method that inhibits male hormone secretion or blocks hormone production by surgery, since a significant portion of prostate cancer cells multiply androgen-dependently. This method has a temporary therapeutic effect in more than 80% of patients, such as cancer suppression or lesion reduction. However, even patients who responded well to transient hormonal therapy progressed to hormone-refractory prostate cancer (HRPC) after a certain period of time, and those who die within one year of the mean diagnosis. In the case of HRPC, conventional anticancer drugs, chemotherapy, or radiation therapy do not show a great effect, so a new treatment method is required (Fong, L. et al., Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer.J. Immunol. 159: 3113. (1997).

Recently, with the possibility of immunotherapy using cytokines and dendritic cells, immunotherapy using dendritic cell therapy (DC vaccine) has emerged as the next generation treatment for HRPC patients (Fong, L. et al., Dendritic cells in cancer immunotherapy. Annu. Rev. Immunol. 18: 245. (2000); Xue BH. Et al., Induction of human cytotoxic T lymphocytes specific for prostate specific antigen.Prostate. 30: 73.78. (1997)). For the clinical trial of immunotherapy using dendritic cells, the effectiveness and safety of the animal model should be confirmed first. However, there is no animal model for prostate cancer to evaluate the efficacy of dendritic cell vaccine against human prostate cancer.

On the other hand, a sense songhyang (Nardostachytis Rhizoma) is used as the root of a perennial plant of a sense songhyang (nardostachys Batalin chinensis) stomach pain, stomach cramps, thoracoabdominal coupon, neurogenic gastrointestinal disorders, vomiting, headache, or the like, respectively. Nardostachys jatamansi (NJ) has been used extensively as a tonic, irritant and anticonvulsant in several Asian countries, as well as to treat epilepsy, pathological excitement, palpitations and spasms (Bagchi, A., et al. , Planta Med., 57, 9697 (1991)). Various sesquiterpenes, lignans, and neolignans such as Jatamansic acid and Jatamansone are present in the roots (Chatterji, A, et al., National Institute of Science Communication, vol. 5, pp 99-100 (1997); Arora, RB., Indian Council of Medical Research, vol. 51 (1965)).

Perennial perennial persimmon roots include 1-aristol-2-one, nardostachone, 1,8,9,10-tetrad-hydroaristolan-2- components such as one) are contained. The self-acting effect of the sensational sensation relieves pain caused by abdominal pain and chest abdominal pain, and is also applied to neuropathic pain and headache. Wash each affected area by adding water to it. It acts on the central nervous system and has a calming effect, such as heel chogeun (尉 草根). In people with a constant heart rate, heart rate control is remarkable, and smooth muscle spasm of the bronchus, small intestine, large intestine, and uterus is released. Minor but also antibacterial. Because it is fragrant, it has the effect of false positive effect, so it can alleviate symptoms such as abdominal pain and loss of appetite caused by falsehood. It is also combined with all spices to make spices. The rooted water of the incense incense has been used for mental disorders, insomnia, blood disorders and circulatory disorders (Uniyal, MR., Et al., J. Res. Indian Med. 4, 83 (1969)), the main therapeutic component of the incense incense Is nardosinone that enhances neuronal activity and central nervous system (CNS) effects (Li, p. Et al., Journal of Pharmacology Science, 93, 122-125 (2003)). In addition, the extract of saengsam fragrance protects mice from thioacetamide induced liver damage (Bagchi, A., et al.). However, nothing has been disclosed or disclosed in this document with regard to prostate cancer-related diseases of S. aureus.

Accordingly, the present inventors completed the present invention by confirming that the extract of the extract of Persimmon can effectively kill the prostate cancer cells while studying the herbal medicine for the extract.

An object of the present invention to provide a composition for the treatment of prostate cancer containing the extract persimmon flavor as an active ingredient.

In order to achieve the above object, the present invention provides a composition for the prevention and treatment of prostate cancer containing an organic solvent extract of Nardostachyos Rhizoma as an active ingredient.

Hereinafter, the present invention will be described in detail.

In the composition for preventing and treating prostate cancer of the present invention, the organic solvent is preferably ethanol, wherein the ethanol extract is more preferably extracted at 50 ° C. for 24 hours or dried and concentrated at 45 ° C. under reduced pressure, Most preferably, the ethanol is 95%. The composition of the present invention contains the extract of Persimmon as an active ingredient, and may further include a pharmaceutically acceptable carrier or diluent.

The persimmon extract of the present invention is possible at any site of persimmon, but is preferably extracted from the root. The extraction solution may be obtained by extraction with water or an organic solvent, and examples of the organic solvent may include lower alcohols, acetone, chloroform, methylene chloride, ether, ethyl acetate, and hexane. Lower alcohols include methanol, ethanol, propanol and butanol, with ethanol being most preferred.

Specifically, 1 to 5 times, preferably 3 times, 95% ethanol is added to the dried persimmon fragrance or powder, and 10 to 100 hours, preferably 15 at a temperature of 20 to 100 ° C, preferably 40 to 60 ° C. To 40 hours, more preferably, for 24 hours after extraction can be filtered to prepare an ethanol extract of persimmon flavor. Preferably, the filtrate obtained by filtering the extract may be concentrated under reduced pressure. In the above extraction methods, the extraction process may be repeated two or more times as necessary, and the extract obtained after filtration may be lyophilized or dried under reduced pressure to obtain a powder form.

The anticancer composition of the present invention contains a persimmon fragrance as an active ingredient, and may further include a pharmaceutically acceptable carrier or diluent. The "pharmaceutically acceptable carrier" is a pharmaceutically acceptable substance such as a liquid or solid filler, diluent, excipient or solvent which serves to transport the active ingredient from one organ or part of the body to another organ or part of the body. , Composition or vehicle.

In one embodiment of the present invention, the composition of the present invention alone or in radiation therapy or chemotherapy (cell growth arrest or cytotoxic substance, antibiotic-type substance, alkylating agent, anti-metabolic substance, hormone, immuno-agent, interferon type Substances, cyclooxygenase inhibitors (e.g. COX-2 inhibitors), metallomatrix protease inhibitors, teromerase inhibitors, tyrosine kinase inhibitors, anti-growth factor receptor materials, anti-HER substances, anti-EGFR substances, anti Other anticancer agents such as angiogenesis agents, farnesyl transferase inhibitors, ras-raf signal conduction pathway inhibitors, cell cycle inhibitors, other cdk inhibitors, tubulin binders, topoisomerase I inhibitors, topoisomerase II inhibitors, etc. It can be administered in combination with treatment. By way of example, the compositions of the present invention may include one or more chemotherapeutic agents optionally contained in liposome formulations (e.g., taxanes, taxane derivatives, encapsulated taxanes, CPT-11, camptothecin derivatives, anthracycline glycosides, doxorubicin, idarubicin). Leucine, epirubicin, etoposide, navelbine, vinblastine, carboplatin, cisplatin, estramustine, celecoxib, schgen SU-5416, schgen SU-6668, herceptin and the like). have. When formulated at a constant dose, such combinations use the compositions of the invention within the dosage ranges described below and other pharmaceutically active substances within the approved dosage ranges. The compositions of the present invention can be used sequentially with known anticancer agents when the combination formulation is inappropriate. The effective daily dose of the active ingredient in the anticancer composition of the present invention may be determined according to the age, sex, site of application, frequency of administration, administration time, formulation, type of adjuvant, and the like.

The composition of the present invention can be administered via a route commonly used for anticancer treatment. In addition, the anticancer composition of the present invention may be prepared in various formulations depending on the dosage form. For example, it may be administered in oral form of tablets, capsules, dragees or film encapsulated tablets, solutions or suspensions, parenteral forms of intramuscular, intravenous and / or intrathecal and / or intrathecal injection or infusion. For example, oral solids may be used in combination with the active compound in diluents (e.g. lactose, dextrose, sucrose, cellulose, corn starch or potato starch), lubricants (e.g. silica, talc, stearic acid, Magnesium or calcium stearate and / or polyethylene glycol), binders (e.g. starch, arabic gum, gelatin methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone), disintegrants (e.g. starch, alginic acid, Alginate or sodium starch glycolate), formal mixtures, dyes, sweeteners, wetting agents (eg lecithin, polysorbates, laurylsulfate) and pharmacologically inert substances generally used in pharmaceuticals. These agents can be prepared by known methods, for example by means of mixing, granulating, tableting, dragging or film-coating processes. Liquid dispersions for oral administration can be, for example, syrups, emulsions and suspensions. Suspensions and emulsions may contain, for example, natural gums, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose or polyvinyl alcohol as carriers. Suspensions or solutions for intramuscular injection, together with the active compound, may be used as a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols (e. G. Propylene glycol) and, if necessary, in suitable amounts of lidocaine hydrochloride. It may contain. Solutions for intravenous injection or infusion may, for example, contain sterile water or preferably in the form of sterile, aqueous, isotonic saline solutions or carrier propylene glycol.

In a specific embodiment of the present invention, the ethanol extracts of the extracts kill 86% and 82% of PC-3 or DU 145 prostate cancer cells at 100 μg / ml, respectively. The above results demonstrate that the extract of Persimmon extract of the present invention has excellent killing activity of PC-3 or DU 145 prostate cancer cells, and further has prostate cancer treatment and prophylactic activity.

The composition of the present invention is administered in a pharmaceutically effective amount. As used herein, the term “pharmaceutically effective amount” means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level refers to a patient's sexually transmitted disease, age, severity, and drug activity. , Drug sensitivity, time of administration, route of administration and rate of release, duration of treatment, factors including concurrently used drugs, and other factors well known in the medical arts. The compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents. It may be single or multiple doses. Taking all of the above factors into consideration, it is important to administer an amount that can obtain the maximum effect in a minimum amount without side effects, and can be easily determined by those skilled in the art. The method of administering the composition comprising the extract or compound prepared according to the preparation method of the present invention is preferably oral administration or intravenous administration. In general, when the effective dose is oral administration, it is usually 1 to 1 time per adult. 500 mg / kg is preferred, and in the case of intravenous administration, 1 to 100 mg / kg is preferred, and may be administered 2-3 times a day. Dosage levels for a particular patient may vary depending on sex, age, affection status, diet, time of administration, method of administration, drug mixture, the condition of the patient and the incidence of neurological disease.

In the present invention, as a result of injecting the persimmon extract of the present invention into PC-3 or DU 145 prostate cancer cells, it was confirmed that PC-3 or DU 145 prostate cancer cells die (see FIGS . 1 and 2 ). In addition, as a result of flow cytometry and Western blotting, the extract of saenghyanghyang can prevent prostate cancer cells of PC-3 and DU 145 cells, which are human prostate cancer cell lines, in a specific cell cycle to stop cell division in apoptosis (apoptosis process). apoptosis) process (see FIGS . 3 and 4 ). In addition, the extract of Persimmon extract activates Caspase 3, which affects NF-κB cell signal of prostate cancer cells and induces apoptosis (see FIG. 5 ). Thus, it can be seen that the extract of Seng Songhyang has a prostate cancer treatment effect.

As described above, the extract of the present invention, the extract of the present invention inhibits the growth of prostate cancer cells and induces apoptosis. Therefore, the composition for treating prostate cancer according to the present invention will be very effective for the treatment of patients with prostate cancer.

1 is a result of Alamar Blue analysis to determine the effect of the introduction of the extract from Example 1 in PC-3 cells, human prostate cancer cell line on the growth of prostate cancer cells, wherein the X-axis is the concentration of the extract And the Y axis represents the survival rate of surviving human prostate cancer PC-3 cells.

Figure 2 is the result of Alamar Blue analysis to determine the effect of the introduction of the extract of the extract from Example 1 on the growth of prostate cancer cells in DU 145 cells, a human prostate cancer cell line, wherein the X-axis is the concentration of the extract , Y axis shows survival rate of surviving human prostate cancer DU 145 cells.

Figure 3 is a flow cytometry result to determine the effect of the introduction of the extract of the sensation incense obtained in Example 1 in PC-3 cells, a human prostate cancer cell line on the prostate cancer cells to stop the cell cycle and apoptosis.

Figure 4 is a flow cytometry result to determine the effect of the introduction of the extract of the extract from Example 1 in the human prostate cancer cell line DU 145 to stop the prostate cancer cells cell cycle and apoptosis.

FIG. 5 shows the activation of Caspase 3 to induce quantitative changes and apoptosis of I-κBβ protein in order to investigate the effect of the introduction of the extract of Persimmon on the NF-κB signal of prostate cancer cells in PC-3, a human prostate cancer cell line. The result of analysis by Western blotting method.

Hereinafter, the present invention will be described in more detail with reference to Examples. However, these examples are for illustrative purposes only and are not intended to limit the scope of the present invention.

Example 1 Preparation of Persimmon Extract

3 kg of Gamsong (Chinese) purchased from Seoul medicinal herb was dried and ground for 5 days at the shade and room temperature. The ground persimmon was immersed in 30 L of 95% ethanol and extracted at 50 ° C. for 24 hours. This was filtered through filter paper, dried and concentrated under reduced pressure at 45 ° C. to obtain 311 g of the total extract, which was stored at −20 ° C.

Example 2 Preparation and Treatment of Human Prostate Cancer Cell Line

The human prostate cancer cell lines PC-3 and DU 145 used in the present invention were obtained from ATCC (American Type Culture Collection, Manassas, VA, USA) and used for experiments. Specifically, PC-3 and DU 145 cell lines were treated with DMEM (Dulbeco's Modified Eagle's Medium) medium containing 10% fetal bovine serum (FBS) (Welgene) at 37 ° C. and 5% CO ₂ . It was kept as it was, and it was passaged for 2-3 days.

Example 3 Effect of Persimmon Extract on Growth of Prostate Cancer Cells

In order to determine the effect of the extract from Example 1 on the growth of prostate cancer cells, the ethanol extract of the extract of Persimmon incense on PC-3 and DU 145 cells, which are human prostate cancer cells, was treated for 48 hours and Alamar Blue analysis was performed. Was implemented. The Alamar Blue assay is a modified form of the MTT assay, in which a specific enzyme degrades a living cell and then measures the fluorescence intensity of the product as the compound breaks down to determine the relative number of living cells after treatment. I am an experimental method. It will be described in more detail below.

4 x 10 per each well in a 96 well plate³ PC-3 and DU 145 cells were seeded and incubated for 24 hours. Melon Fragrance of Example 1 dissolved in DMSO (dimethyl sulfoxide) When the ethanol extract was treated at concentrations of 0 to 100 μg / ml (specifically, concentrations of 0, 3.125, 6.25, 12.5, 25, 50 and 100 μg / ml, respectively) for 48 hours, the degree of inhibition of cell growth was confirmed. (Table 1 and Table 2). After treatment of each concentration of extract, 20 μl of Alamar Blue reagent was added to 0.2 ml of cell culture filled in each well in a 96-well plate, and the plates were incubated for 2 hours in an incubator. The plate was slowly shaken to evenly react the cells in each well, and the intensity of fluorescence was measured by Fluorescence Microplate Reader (Molecular Devices Corp.) at 590 nm while irradiating irradiated light at a wavelength of 544 nm. Survival rates of -3 and DU 145 human prostate cancer cells are also shown in FIGS. 1 and 2.

Table 1

Resonance Aroma Concentration of Example 1	Experiment 1	Experiment 2	Experiment 3	PC-3 cell viability (average)	Standard Deviation
0 μg / ml	100%	100%	100%	100%	0%
3.125 μg / ml	112%	95%	95%	100%	10%
6.25 μg / ml	110%	98%	93%	101%	9%
12.5 μg / ml	96%	84%	97%	92%	7%
25 μg / ml	60%	49%	55%	55%	6%
50 μg / ml	40%	31%	35%	35%	4%
100 μg / ml	16%	11%	13%	14%	2%

TABLE 2

Resonance Fragrance Concentration of Example 1	Experiment 1	Experiment 2	Experiment 3	DU 145 cell viability (average)	Standard Deviation
0 μg / ml	100%	100%	100%	100%	0%
3.125 μg / ml	91%	110%	101%	101%	10%
6.25 μg / ml	101%	111%	106%	106%	5%
12.5 μg / ml	108%	100%	104%	104%	4%
25 μg / ml	78%	80%	78%	78%	One%
50 μg / ml	34%	33%	32%	33%	One%
100 μg / ml	20%	19%	16%	18%	2%

As a result, as shown in Table 1 and Table 2 (see Figs. 1 and 2), the higher the treatment concentration of the sensational fragrance, the growth of cancer cells was reduced, and it can be seen that the sensational aroma has an anticancer effect.

Example 4 Effect of Persimmon Extract on Cell Division Cycle of Prostate Cancer Cells

Flow Cytometry was performed to investigate the effects of the extract of Persimmon on the cell division cycle of cancer cells. Flow cytometry is a method to quickly identify the characteristics of a cell as it passes through the detection zone. When staining the cell nucleus with a fluorescent material, the flow cytometry can be determined. .

Specifically, PC-3 and DU 145 cells were seeded in 6-well plates at about 2.4 × 10 ⁵ cells per well and incubated for 24 hours. Cells were administered with 100 μg / ml of Persimmon extract and allowed to stand for 24 hours. The culture medium in each well was removed from the 6-well plate and washed twice with PBS (phosphate-buffered saline). The attached cells were suspended by treatment with trypsin-EDTA solution, transferred to microtubes and centrifuged to recover the cells. The recovered cells were washed with PBS, centrifuged and suspended in cold ethanol. Cells suspended in ethanol were stored at 4 ° C to fix the cells, centrifuged and washed with PBS. The washed cells were suspended in 500 μl of PI solution (50 μg / ml of Propidium Iodide, 10 μg / ml of RNase A) and stored at 37 ° C. for 30 minutes to stain nuclei, and 2 ml of PBS was added thereto. Cells suspended in solution were analyzed by flow cytometry (FACS; BD biosciences), and cell cycles and apoptosis of PC-3 and DU 145 human prostate cancer cells were shown in FIGS. 3 and 4, respectively.

As a result, as shown in Figs. 3 and 4, the cancer cells treated with the extracts of saccharin extract were found to be stationary in a specific cell cycle compared to the control group, and the apoptosis process, which is an apoptosis process, was in progress. From this, it can be seen that the persimmon extract stops the division of cancer cells and leads to apoptosis.

Example 5 Effect of Persimmon Extract on NF-κB Cell Signaling of Prostate Cancer Cells

Quantitative Changes of I-κBβ Proteins Inhibiting NF-κB Activity after Treatment of Persimmon Extracts on Human Prostate Cancer Cells in order to Investigate the Effect of Persimmon Extracts on NF-κB Cell Signals Inducing Cancer Cell Growth Was confirmed by Western blotting method.

Specifically, PC-3 cells were cultured to grow 60-70% in a 60 mm dish, and then the persimmon extract was treated with a concentration of 0-100 μg / ml. After 24 hours, the culture medium was removed from the cells in culture, washed with PBS, and treated with NP-40 solution to obtain cell lysate. The cell lysate was centrifuged to recover the supernatant in which the cellular protein was dissolved, and the sample was prepared for electrophoresis after measuring the concentration. The prepared samples were electrophoresed and Western blotting was performed to analyze the amount of I-κBβ protein with I-κBβ antibody, and the results are shown in FIG. 5.

As shown in FIG. 5, the extract of S. eryngii inhibits prostate cancer cell division by increasing the amount of I-κBβ protein and inhibiting NF-κB activity.

Example 6 Effect of Persimmon Extract on Apoptosis of Prostate Cancer Cells

In order to examine the effect of the extract of Apricot aloe vera on apoptosis of cancer cells, Western blotting was used to confirm the activation of Caspase 3, which induces apoptosis process after treating the extract of Aloe vera extract to human prostate cancer cells.

Specifically, PC-3 cells were cultured to grow 60-70% in a 60 mm dish, and then the persimmon extract was treated with a concentration of 0-100 μg / ml. After 24 hours, the culture medium was removed from the cells in culture, washed with PBS, and treated with NP-40 solution to obtain cell lysate. The cell lysate was centrifuged to recover the supernatant in which the cellular protein was dissolved, and the sample was prepared for electrophoresis after measuring the concentration. The prepared samples were electrophoresed and Western blotting was performed to analyze the degree of Caspase 3 activation with the Caspase 3 antibody, and the results are shown in FIG. 5.

As shown in FIG. 5, the extract of S. eryngma was confirmed that Caspase 3, which leads to apoptosis of cancer cells, was activated, and it can be seen that the sensational aroma effectively leads to apoptosis of cancer cells, thereby exhibiting an anticancer effect.

Preparation Example 1 Preparation of a Prostate Cancer Therapeutic Agent Containing Persimmon Extract as an Active Ingredient

The present inventors have confirmed that the prostate cancer treatment efficacy of the extract persimmon through the embodiment of the prostate cancer to prepare a prostate cancer treatment containing the extract as an active ingredient as follows.

<1-1> Soft Gelatin Capsules Containing Sweet Persimmon Extract

Honey extract 20%

Vitamin C 4.5%

Vitamin D ₃ 0.001%

Manganese Sulfate 0.1%

10% beeswax

Palm oil 25%

Safflower Seed Oil 30.399%

 <1-2> Preparation of Intravenous Formulation Containing Persimmon Extract

Persimmon Extract 0.2%

Mannitol 0.3%

Saline 9.5%

<1-3> tablet containing the extract of Persimmon

Honey extract 35%

Vitamin C 10%

Vitamin D ₃ 0.001%

Manganese Sulfate 0.1%

Crystalline cellulose 25.0%

Lactose 17.999%

Magnesium Stearate 2%

Claims (6)

1. A composition for preventing and treating prostate cancer, comprising an organic solvent extract of Nardostachyos Rhizoma as an active ingredient.
2. The composition for preventing and treating prostate cancer according to claim 1, wherein the organic solvent is ethanol.
3. According to claim 2, wherein the ethanol extract is a composition for preventing and treating prostate cancer, characterized in that extracted for 24 hours at 50 ℃.
4. The composition for preventing and treating prostate cancer according to claim 2 or 3, wherein the ethanol extract is dried and concentrated at 45 ° C under reduced pressure.
5. 4. The composition for preventing or treating prostate cancer according to claim 2 or 3, wherein the ethanol is 95%.
6. According to claim 1, wherein the composition is a composition for preventing and treating prostate cancer, characterized in that it comprises a pharmaceutically acceptable carrier or diluent.

Images